Comparative Pharmacology
Head-to-head clinical analysis: TESTOSTERONE CYPIONATE ESTRADIOL CYPIONATE versus VIRILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTOSTERONE CYPIONATE ESTRADIOL CYPIONATE versus VIRILON.
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE vs VIRILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone cypionate is a prodrug of testosterone, which binds to androgen receptors and modulates gene expression, promoting male secondary sex characteristics and anabolic effects. Estradiol cypionate is a prodrug of estradiol, which binds to estrogen receptors and regulates gene transcription involved in female reproductive development and maintenance.
Testosterone replacement therapy; binds to androgen receptors, leading to activation of androgen-responsive genes and promotion of male secondary sexual characteristics.
Testosterone cypionate 50-200 mg and estradiol cypionate 2-10 mg intramuscularly every 2-4 weeks.
200 mg intramuscularly every 2 weeks for androgen replacement therapy in adult males.
None Documented
None Documented
Testosterone cypionate: approximately 8 days; estradiol cypionate: approximately 8-10 days. Clinical context: steady-state reached in 3-5 weeks.
Terminal elimination half-life is approximately 3–4 hours for methyltestosterone; however, the pharmacologic effect persists longer due to active metabolites, supporting once-daily dosing.
Renal (90% as glucuronide and sulfate conjugates, less than 5% as unchanged drug); fecal (approximately 10%).
Approximately 90% of administered methyltestosterone is excreted as glucuronide and sulfate conjugates in urine; less than 5% appears in feces as unchanged drug and metabolites.
Category D/X
Category C
Androgen
Androgen